The Wolf in Sheep’s Clothing – Neuroendocrine Tumors (NETs)

Released On
June 28, 2021

Expires On
June 28, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Endocrinology, Gastroenterology, Pathology, Primary Care, Radiology, Surgery

Topic(s)
Primary Care, Gastric Cancer, Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and P2P Syncro.

This activity is supported in part by an independent education grants from Ipsen Pharmaceuticals and Sun Pharma.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hour
  • Physician Assistants — 1.0 CE Credit
  • Pharmacists — 1.0 Contact Hour

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for physicians, PAs, pharmacists, nurse practitioners, registered nurses and other HCPs in primary care, GI, and oncology practice.

Program Overview

Neuroendocrine tumors are often misdiagnosed as irritable bowel syndrome and other diseases. They can also be found incidentally by colonoscopy, EGD, or CT scan. The program describes the next steps in primary care, GI, and oncology practice. Brief takeaways are included.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • To raise suspicion and be aware of common misdiagnoses
  • To describe the diagnostic work up and initiate treatment
 

Faculty

FACULTY_NAME

David C. Metz, MD

Dr. David Metz is a gastroenterologist and professor of medicine at the Perelman School of Medicine, University of Pennsylvania. Dr. Metz is a recognized leader in the field of neuroendocrine tumors (NETs). He has served as the co-director of the NET program at the University of Pennsylvania and has decades of experience in caring for patients with the disease. He has published extensively on the diagnosis and treatment of NETs.

FACULTY_NAME

Daniel M. Halperin, MD

Dr. Daniel Halperin is an oncologist and assistant professor at the University of Texas MD Anderson Cancer Center. In addition to providing care to patients with NETs, Dr. Halperin works with a team of scientists to better understand the molecular underpinning of the disease and he leads clinical trials of novel NET treatments. He is a member of the NET guideline committee of the National Comprehensive Cancer Network.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and P2P Syncro. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-21-2843-H01-P)
Type of Activity: Knowledge

Continuing Physician Assistant Education

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until [Expiration Date]. PAs should only claim credit commensurate with the extent of their participation.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

David C. Metz, MD
• Consulting Fees: Crinetics and Lexicon.

Daniel M. Halperin, MD
• Consulting Fee from: from Ipsen, Advanced Accelerator Applications, Isotopen Technologien Munchen, Chimeric Therapeutics, and Curium.
• Contracted Research with funding support provided by: Advanced Accelerator Applications, Genentech, Tarveda, ThermoFisher Scientific, Incyte, and TerSera.

The PIM planners and managers have nothing to disclose. The P2P Syncro planners and managers have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

 

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information

If you have questions regarding the certification of this activity, please contact us via email at inquiries@pimed.com.